Charles Schwab Investment Management Inc. Buys 8,913 Shares of Fresenius Medical Care AG (NYSE:FMS)

Charles Schwab Investment Management Inc. raised its stake in Fresenius Medical Care AG (NYSE:FMS) by 40.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 31,074 shares of the company’s stock after buying an additional 8,913 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Fresenius Medical Care were worth $704,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Jones Financial Companies Lllp raised its position in Fresenius Medical Care by 80.5% during the fourth quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company’s stock valued at $102,000 after purchasing an additional 2,012 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Fresenius Medical Care by 192.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock valued at $28,000 after buying an additional 806 shares in the last quarter. US Bancorp DE lifted its position in Fresenius Medical Care by 8.6% in the 4th quarter. US Bancorp DE now owns 20,429 shares of the company’s stock worth $463,000 after buying an additional 1,610 shares during the last quarter. QRG Capital Management Inc. boosted its stake in Fresenius Medical Care by 16.7% in the fourth quarter. QRG Capital Management Inc. now owns 67,973 shares of the company’s stock worth $1,539,000 after buying an additional 9,706 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in Fresenius Medical Care by 5.8% during the fourth quarter. Bank of New York Mellon Corp now owns 21,951 shares of the company’s stock valued at $497,000 after acquiring an additional 1,205 shares during the last quarter. 8.37% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

FMS has been the subject of a number of recent research reports. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. StockNews.com upgraded shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Finally, Truist Financial lifted their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Monday, January 6th.

Fresenius Medical Care Stock Up 0.7 %

Shares of Fresenius Medical Care stock opened at $24.94 on Tuesday. The company’s 50 day moving average price is $24.06 and its 200-day moving average price is $22.57. Fresenius Medical Care AG has a 52-week low of $17.93 and a 52-week high of $25.25. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The stock has a market capitalization of $14.64 billion, a price-to-earnings ratio of 20.61, a P/E/G ratio of 0.76 and a beta of 0.99.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.